|
COX-2 in Cancer: Bibliography
Ali, S. et al. Simultaneous Targeting of the Epidermal Growth Factor Receptor and Cyclooxygenase-2 Pathways for Pancreatic Cancer Therapy. Molecular Cancer Therapeutics 4, 1943-1951 (2005).
Altorki, N. et al. Celecoxib, a Selective Cyclo-Oxygenase-2 Inhibitor, Enhances the Response to Preoperative Paclitaxel and Carboplatin in Early-Stage Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 21, 2645-2650 (2003).
Altorki, N. et al. Chemotherapy Induces the Expression of Cyclooxygenase-2 in Non-Small Cell Lung Cancer. Clinical Cancer Research 11, 4191-4197 (2005).
Backlund, M. et al. Novel Strategies for the Treatment of Lung Cancer: Modulation of Eicosanoids. Journal of Clinical Oncology 26, 825-827 (2008).
Burris, H. et al. Improvements in Survival and Clinical Benefit with Gemcitabine as First-Line Therapy for Patients with Advanced Pancreas Cancer: A Randomized Trial. Journal of Clinical Oncology 15, 2403-2413 (1997).
Chang, Y. et al. RhoA Mediates Cyclooxygenase-2 Signaling to Disrupt the Formation of Adherens Junctions and Increase Cell Motility. Cancer Research 66, 11700-11708 (2006).
Chen, Z. et al. Simultaneously Targeting Epidermal Growth Factor Receptor Tyrosine Kinase and Cyclooxygenase-2, an Efficient Approach to Inhibition of Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research 10, 5930-5939 (2004).
Clevers, H. Colon Cancer - Understanding How NSAIDs Work. The New England Journal of Medicine 354, 761-763 (2006).
Csiki, I. and Johnson, D. Did Targeted Therapy Fail Cyclooxygenase Too? Journal of Clinical Oncology 24, 4798-4800 (2006).
Csiki, I. et al. Targeting Cyclooxygenase-2 in Recurrent Non-Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel. Clinical Cancer Research 11, 6634-6640 (2005).
Dang, C. et al. Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments. Clinical Cancer Research 10, 4062-4067 (2004).
Dirix, L. et al. Treatment of Advanced Hormone-Sensitive Breast Cancer in Postmenopausal Women with Exemestane Alone or in Combination with Celecoxib. Journal of Clinical Oncology 26, 1253-1259 (2008).
Dohadwala, M. et al. Cyclooxygenase-2-Dependent Regulation of E-Cadherin: Prostaglandin E2 Induces Transcriptional Repressors ZEB1 and Snail in Non-Small Cell Lung Cancer. Cancer Research 66, 5338-5345 (2006).
Edelman, M. et al. Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy -- Cancer and Leukemia Group B Trial 30203. Journal of Clinical Oncology 26, 848-855 (2008).
Engelman, J. and Cantley, L. A Sweet New Role for EGFR in Cancer. Cancer Cell 13, 375-376 (2008).
Engelman, J. et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science 316, 1039-1043 (2007).
Falandry, C. et al. Celecoxib and Exemestane Versus Placebo and Exemestane in Postmenopausal Metastic Breast Cancer Patients: A Double-Blind Phase III GINECO Study. Breast Cancer Research and Treatment (2008).
Fidler, M. et al. The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non-Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib. Clinical Cancer Research 14, 2088-2094 (2008).
FitzGerald, G. Coxibs and Cardiovascular Disease. The New England Journal of Medicine 351, 1709-1711 (2004).
Friedman, H. and Bigner, D. Glioblastoma Multiforme and the Epidermal Growth Factor Receptor. The New England Journal of Medicine 353, 1997-1999 (2005).
Gately, S. and Li, W. Multiple Roles of COX-2 in Tumor Angiogenesis: A Target for Antiangiogenic Therapy. Seminars in Oncology 31, 2-11 (2004).
Gauthier, M. et al. Abrogate Response to Cellular Stress Identifies DCIS Associate with Subsequent Tumor Events and Defines Basal-like Breast Tumors. Cancer Cell 12, 1-13 (2007).
Geyer, C. et al. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. The New England Journal of Medicine 355, 2733-2743 (2006).
Graham, D. COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk: The Seduction of Common Sense. The Journal of the American Medical Assocication, (2006).
Gross, N. et al. Levels of Prostaglandin E Metabolite, the Major Urinary Metabolite of Prostaglandin E2, Are Increased in Smokers. Clinical Cancer Research 11, 6087-6093 (2005).
Hawk, E. et al. COX-2 in Cancer - A Player That's Defining the Rules. Journal of the National Cancer Institute 94, 545-546 (2002).
Hida, T. et al. Cyclooxygenase-2 Inhibitor Induces Apoptosis and Enhances Cytotoxicity of Various Anticancer Agents in Non-Small Cell Lung Cancer Cell Lines. Clinical Cancer Research 6, 2006-2011 (2000).
Howe, L. et al. HER-2/Neu-Induced Mammary Tumorigenesis and Angiogenesis Are Reduce in Cyclooxygenase-2 Knockout Mice. Cancer Research 65, 10113-10119 (2005).
Joki, T. et al. Expression of Cyclooxygenase-2 in Human Glioma and in Vitro Inhibition by a Specific COX-2 Inhibitor, NS-398. Cancer Research 60, 4026-4031 (2000).
Kastrissios, H. et al. Development of a Predictive Pharmacokinetic Model for a Novel Cyclooxygenase-2 Inhibitor. Journal of Clinical Pharmacology 46, 537-548 (2006).
Kearney, P. et al. Do Selective Cyclo-Oxygenase-2 Inhibitors and Traditional Non-Steroidal Anti-Inflammatory Drugs Increase the Risk of Atherothrombosis? Meta-Analysis of Randomised Trials. British Medical Journal 332, 1302-1308 (2006).
Kerr, D. et al. Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer. The New England Journal of Medicine 357, 360-369 (2007).
Kyrsan, K. et al. Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance. Journal of Thoracic Oncology 3, 107-124 (2008).
Lanza-Jacoby, S. et al. Effect of Simultaneous Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 in HER-2/Neu-Positive Breast Cancer. Clinical Cancer Research 12, 6161-6169 (2006).
Lippman, S. et al. Combined Targeting of the Epidermal Growth Factor Receptor and Cyclooxygenase-2 Pathways. Clinical Cancer Research 11, 6097-6099 (2005).
Maheswaran, S. et al. Detection of Mutations in EGFR in Circulating Lung-Cancer Cells. The New England Journal of Medicine 359, (2008).
Masferrer, J. et al. Antiangiogenic and Antitumor Activities of Cyclooxygenase-2 Inhibitors. Cancer Research 60, 1306-1311 (2000).
Matsubayashi, H. et al. Tumor COX-2 Expression and Prognosis of Patients with Resectable Pancreatic Cancer. Cancer Biology & Therapy 6, 1569-1575 (2007).
McGettigan, P. and Henry, D. Cardiovascular Risk and Inhibition of Cyclooxygenase: A systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2. The Journal of the American Medical Association 296, (2006).
Mellinghoff, I. et al. Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors. The New England Journal of Medicine 13, 2012-2025 (2005).
Mellinghoff, I. et al. PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors. Clinical Cancer Research 13, 378-381 (2007).
Moberly, J. et al. A Randomized, Double-Blind, One-Week Study Comparing Effects of a Novel COX-2 Inhibitor and Naproxen on the Gastric Mucosa. Digestive Diseases and Sciences 52, 442-450 (2007).
Moberly, J. et al. A Randomized, Double-Blind, Celecoxib- and Placebo-Controlled Study of the Effectiveness of CS-706 in Acute Postoperative Dental Pain. Clinical Therapeutics 29, 399-412 (2007).
Moore, M. et al. Erlotinib Plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 25, (2007).
Murphey, L. et al. Quantification of the Major Urinary Metabolite of PGE2 by a Liquid Chromatographic/Mass Spectrometric Assay: Determination of Cyclooxygenase-Specific PGE2 Synthesis in Healthy Humans and Those with Lung Cancer. Analytical Biochemistry 334, 266-275 (2004).
Mutter, R. et al. A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non-Small Cell Lung Cancer. Clinical Cancer Research 15, 2158-2165 (2009).
Oitate, M. Covalent Binding of Radioactivity from [14C]Rofecoxib, but not [14C]Celecoxib or [14C]CS-706, to the Arterial Elastic of Rats. Drug Metabolism and Disposition 34, 1417-1422 (2006).
Osbourne, C. K. Crosstalk between Estrogen Receptor and Growth Factor Receptor Pathways as a Cause for Endocrine Therapy Resistance in Breast Cancer. Clinical Cancer Research 11, 856s-870s (2005).
Reckamp, K. et al. A Phase I Trial to Determine the Optimal Biological Dose of Celecoxib when Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research 12, 3381-3388 (2006).
Ristimaki, A. et al. Prognostic Significance of Elevated Cyclooxygenase-2 Expression in Breast Cancer. Cancer Research 62, 632-635 (2002).
Ritter, A. et al. Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network. Clinical Cancer Research 13, 4909-4919 (2007).
Rohatagi, S. et al. Predictive Population Pharmacokinetic/Pharmacodynamic Model for a Novel COX-2 Inhibitor. Journal of Clinical Pharmacology 47, 1-13 (2007).
Salhab, M. et al. Cyclooxygenase-2 mRNA Expression Correlates With Aromatase Expression in Human Breast Cancer. Journal of Surgical Oncology 96, 424-428 (2007).
Salomon, S. et al. Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. The New England Journal of Medicine 352, 1071-1080 (2005).
Sarrio, D. et al. Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype. Cancer Research 68, 989-997 (2008).
Schiffmann, S. et al. The Anti-Proliferative Potency of Celecoxib is Not a Class Effect of Coxibs. Biochemical Pharmacology, (2008).
Senzaki, M. et al. CS-706, A Novel Cyclooxygenase-2 Selective Inhibitor, Prolonged the Survival of Tumor-Bearing Mice When Treated Alone or in Combination with Anti-Tumor Chemotherapeutic Agents. International Journal of Cancer 122, 1384-1390 (2007).
Shaik, M. et al. Enhancement of Antitumor Activity of Docetaxel by Celecoxib in Lung Tumors. International Journal of Cancer 118, 396-404 (2005).
Shono, T. et al. Cyclooxygenase-2 Expression in Human Gliomas: Prognostic Significance and Molecular Correlations. Cancer Research 61, 4375-4381 (2002).
Smith, I. and Dowsett, M. Aromatase Inhibitors in Breast Cancer. The New England Journal of Medicine 348, 2431-2442 (2003).
Solomon, S. et al. Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis. Circulation, 1-10 (2008).
Stoeltzing, O. et al. Regulation of Cyclooxygenase-2 (COX-2) Expression in Human Pancreatic Carcinoma Cells by the Insulin-Like Growth Factor-I Receptor (IGF-IR) System. Cancer Letters 258, 291-300 (2007).
Subbaramaiah, K. et al. Cyclooxygenase-2 Is Overexpressed in HER-2/Neu-positive Breast Cancer. The Journal of Biological Chemistry 258, 291-300 (2007).
Subbaramaiah, K. et al. HER-2/Neu Status Is a Determinant of Mammary Aromatase Activity In vivo: Evidence for a Cyclooxygenase-2-Dependent Mechanism, Cancer Research 66, 5504-5511 (2002).
Thiery, J. Epithelial-Mesenchymal Transitions in Tumour Progression. Nature 2, 442-454 (2002).
Thun, M. et al. Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues. Journal of the National Cancer Institute 94, 252-266 (2002).
Tuynman, J. et al. Cyclooxygenase-2 Inhibition Inhibits c-Met Kinase Activity and Wnt Activity in Colon Cancer. Cancer Research 68, 1213-1120 (2008).
Ushiyama, S. et al. Preclinical Pharmacology Profile of CS-706, a Novel Cyclooxygenase-2 Selective Inhibitor, with Potent Antinociceptive and Anti-Inflammatory Effects. European Journal of Pharmacology 578, 76-86 (2007).
Vermorken, J. et al. Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab as a Single Agent in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy. Journal of Clinical Oncology 25, 2171-2177 (2007).
Wang, D. and DuBois, R. Cyclooxygenase 2-derived Protaglandin E2 Regulates the Angiogenic Switch. Proceeding of the National Academny of Sciences 2, 415-416 (2004).
Weihua, Z. et al. Survival of Cancer Cells in Maintained by EGFR Independent of Its Kinase Activity. Cancer Cell 13, 385-393 (2008).
Xu, K. et al. EGFR Activation Results in Enhances Cyclooxygenase-2 Expression through p38 Mitogen-Activated Protein Kinase-Dependent Activation of the Sp1/Sp3 Transcription Factors in Human Gliomas. Cancer Research 67, 6121-6129 (2007).
Zhang, J. et al. Adverse Effects of Cyclooxygenase-2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials. The Journal of the American Medical Association (2006).
Zhang, X. et al. Coexpression of VEGF-C and COX-2 and its Association with Lymphangiogenesis in Human Breast Cancer. BioMed Central, (2008).
| 
